Drug trials
The Alzheimer’s Research UK Drug Discovery Alliance
Today, we’ve announced the drug discovery experts who will lead the Drug Discovery Alliance.
Scientist Focus: Dr John Davis
Dr John Davis is the new Chief Scientific Officer at the Alzheimer’s Research UK Oxford Drug Discovery Institute.
Dementia researchers are leaving no stone unturned in the hunt for new treatments
To tackle these diseases we need to see research into a range of therapeutic approaches, giving us the best chance of finding effective treatments sooner.
Solanezumab: Is the first disease-modifying treatment for Alzheimer’s on the horizon?
We’re hearing in the news that a new treatment designed to slow Alzheimer’s has shown benefit in one of the final stages of testing in people. So what’s going on?
Why a diabetes drug may offer potential treatment for Alzheimer’s disease
Clinical trials are crucial to understand whether a treatment could help people with Alzheimer’s disease. And that is exactly what scientists are now trying to do with Liraglutide.
Dementia Forum 2015 report: a global call to action
The report shines a necessary spotlight on some of the challenges facing dementia research today.
Boosting the search for new dementia treatments
The Alzheimer’s Research UK Drug Discovery Alliance is a £30m powerhouse of dementia treatment discovery at leading universities for dementia research.
Dementia research in 2014: looking back at our proudest achievements
2014 has seen huge strides in dementia research as our researchers worked tirelessly to uncover clues about how to diagnose, treat and prevent dementia.
The Global Clinical Trials Fund: drugs and dummies
One year since the G8 Dementia Summit, new investment and exciting initiatives are bringing us closer to a treatment for dementia.
In the news: B vitamins and Alzheimer’s disease
A new analysis clinical trials has concluded that taking B vitamins doesn’t slow decline in memory and thinking and is unlikely to prevent Alzheimer’s disease.
